182 related articles for article (PubMed ID: 8661395)
1. Chimeric viruses expressing primary envelope glycoproteins of human immunodeficiency virus type I show increased sensitivity to neutralization by human sera.
McKeating JA; Zhang YJ; Arnold C; Frederiksson R; Fenyö EM; Balfe P
Virology; 1996 Jun; 220(2):450-60. PubMed ID: 8661395
[TBL] [Abstract][Full Text] [Related]
2. Passage of HIV-1 molecular clones into different cell lines confers differential sensitivity to neutralization.
Zhang YJ; Fredriksson R; McKeating JA; Fenyö EM
Virology; 1997 Nov; 238(2):254-64. PubMed ID: 9400598
[TBL] [Abstract][Full Text] [Related]
3. An immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 (HXB2-Env:Ala 582(-->Thr)) decreases viral neutralization by monoclonal antibodies to the CD4-binding site.
Klasse PJ; McKeating JA; Schutten M; Reitz MS; Robert-Guroff M
Virology; 1993 Sep; 196(1):332-7. PubMed ID: 8356803
[TBL] [Abstract][Full Text] [Related]
4. Neutralization sensitivity of a simian-human immunodeficiency virus (SHIV-HXBc2P 3.2N) isolated from an infected rhesus macaque with neurological disease.
Song B; Cayabyab M; Phan N; Wang L; Axthelm MK; Letvin NL; Sodroski JG
Virology; 2004 Apr; 322(1):168-81. PubMed ID: 15063126
[TBL] [Abstract][Full Text] [Related]
5. Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells.
Stamatatos L; Zolla-Pazner S; Gorny MK; Cheng-Mayer C
Virology; 1997 Mar; 229(2):360-9. PubMed ID: 9126249
[TBL] [Abstract][Full Text] [Related]
6. The prolonged culture of human immunodeficiency virus type 1 in primary lymphocytes increases its sensitivity to neutralization by soluble CD4.
Pugach P; Kuhmann SE; Taylor J; Marozsan AJ; Snyder A; Ketas T; Wolinsky SM; Korber BT; Moore JP
Virology; 2004 Mar; 321(1):8-22. PubMed ID: 15033560
[TBL] [Abstract][Full Text] [Related]
7. Stable expression of the transfected HIV-1 env gene in a human B cell line: characterization of gp120-expressing clones and immunobiological studies.
Ahmad A; Ladha A; Cohen EA; Menezes J
Virology; 1993 Feb; 192(2):447-57. PubMed ID: 8421893
[TBL] [Abstract][Full Text] [Related]
8. HIV envelope glycoprotein-induced cell killing by apoptosis is enhanced with increased expression of CD26 in CD4+ T cells.
Jacotot E; Callebaut C; Blanco J; Rivière Y; Krust B; Hovanessian AG
Virology; 1996 Sep; 223(2):318-30. PubMed ID: 8806567
[TBL] [Abstract][Full Text] [Related]
9. Evidence for rapid selection and deletion of HIV-1 subpopulations in vivo by V3-specific neutralizing antibody: a model of humoral-associated selection.
Nara P; Smit L; Dunlop N; Hatch W; Merges M; Waters D; Kelliher J; Krone W; Goudsmit J
Dev Biol Stand; 1990; 72():315-41. PubMed ID: 2282990
[TBL] [Abstract][Full Text] [Related]
10. Amino acid substitutions in the V3 loop are responsible for adaptation to growth in transformed T-cell lines of a primary human immunodeficiency virus type 1.
Harrowe G; Cheng-Mayer C
Virology; 1995 Jul; 210(2):490-4. PubMed ID: 7618285
[TBL] [Abstract][Full Text] [Related]
11. Characterization of a neutralization-escape variant of SHIVKU-1, a virus that causes acquired immune deficiency syndrome in pig-tailed macaques.
Narayan SV; Mukherjee S; Jia F; Li Z; Wang C; Foresman L; McCormick-Davis C; Stephens EB; Joag SV; Narayan O
Virology; 1999 Mar; 256(1):54-63. PubMed ID: 10087226
[TBL] [Abstract][Full Text] [Related]
12. An N-glycan within the human immunodeficiency virus type 1 gp120 V3 loop affects virus neutralization.
Back NK; Smit L; De Jong JJ; Keulen W; Schutten M; Goudsmit J; Tersmette M
Virology; 1994 Mar; 199(2):431-8. PubMed ID: 8122371
[TBL] [Abstract][Full Text] [Related]
13. HIV-1 envelope pseudotyped viral vectors and infectious molecular clones expressing the same envelope glycoprotein have a similar neutralization phenotype, but culture in peripheral blood mononuclear cells is associated with decreased neutralization sensitivity.
Louder MK; Sambor A; Chertova E; Hunte T; Barrett S; Ojong F; Sanders-Buell E; Zolla-Pazner S; McCutchan FE; Roser JD; Gabuzda D; Lifson JD; Mascola JR
Virology; 2005 Sep; 339(2):226-38. PubMed ID: 16005039
[TBL] [Abstract][Full Text] [Related]
14. Increased sensitivity to CD4 binding site-directed neutralization following in vitro propagation on primary lymphocytes of a neutralization-resistant human immunodeficiency virus IIIB strain isolated from an accidentally infected laboratory worker.
Beaumont T; Quakkelaar E; van Nuenen A; Pantophlet R; Schuitemaker H
J Virol; 2004 Jun; 78(11):5651-7. PubMed ID: 15140962
[TBL] [Abstract][Full Text] [Related]
15. DNA vaccines expressing soluble CD4-envelope proteins fused to C3d elicit cross-reactive neutralizing antibodies to HIV-1.
Bower JF; Green TD; Ross TM
Virology; 2004 Oct; 328(2):292-300. PubMed ID: 15464849
[TBL] [Abstract][Full Text] [Related]
16. Impact of V2 mutations on escape from a potent neutralizing anti-V3 monoclonal antibody during in vitro selection of a primary human immunodeficiency virus type 1 isolate.
Shibata J; Yoshimura K; Honda A; Koito A; Murakami T; Matsushita S
J Virol; 2007 Apr; 81(8):3757-68. PubMed ID: 17251298
[TBL] [Abstract][Full Text] [Related]
17. Screening of HIV-1 Env glycoproteins for the ability to raise neutralizing antibody using DNA immunization and recombinant vaccinia virus boosting.
Richmond JF; Mustafa F; Lu S; Santoro JC; Weng J; O'Connell M; Fenyö EM; Hurwitz JL; Montefiori DC; Robinson HL
Virology; 1997 Apr; 230(2):265-74. PubMed ID: 9143282
[TBL] [Abstract][Full Text] [Related]
18. Human immunodeficiency virus type 1 variants isolated from single plasma samples display a wide spectrum of neutralization sensitivity.
Skrabal K; Saragosti S; Labernardière JL; Barin F; Clavel F; Mammano F
J Virol; 2005 Sep; 79(18):11848-57. PubMed ID: 16140761
[TBL] [Abstract][Full Text] [Related]
19. Neutralization and infectivity characteristics of envelope glycoproteins from human immunodeficiency virus type 1 infected donors whose sera exhibit broadly cross-reactive neutralizing activity.
Cham F; Zhang PF; Heyndrickx L; Bouma P; Zhong P; Katinger H; Robinson J; van der Groen G; Quinnan GV
Virology; 2006 Mar; 347(1):36-51. PubMed ID: 16378633
[TBL] [Abstract][Full Text] [Related]
20. Mutations in both gp120 and gp41 are responsible for the broad neutralization resistance of variant human immunodeficiency virus type 1 MN to antibodies directed at V3 and non-V3 epitopes.
Park EJ; Vujcic LK; Anand R; Theodore TS; Quinnan GV
J Virol; 1998 Sep; 72(9):7099-107. PubMed ID: 9696803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
